• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

    5/1/25 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email

    EQ504 targets the aryl hydrocarbon receptor, a clinically validated pathway in the treatment of both skin and gastrointestinal diseases

    EQ504 has a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other immuno-inflammatory therapeutics

    EQ504 data to be presented in three poster presentations next week at the annual meeting of the American Association of Immunologists (AAI)

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced the advancement of a novel and potent aryl hydrocarbon receptor (AhR) modulator (EQ504), which was acquired through the acquisition of Ariagen, a biotechnology company that was majority owned by Equillium's largest investor, Decheng Capital. AhR is critical to barrier organ tissue physiology and immunology, where it maintains barrier function, promotes tissue repair and regeneration, and regulates resident immune cells and anti-inflammatory responses. Modulation of AhR is a clinically validated pathway in the treatment of both skin and gastrointestinal diseases demonstrating high levels of clinical efficacy.

    "We're excited to announce the addition of this promising AhR modulator, representing a target of high strategic interest, to our portfolio of differentiated immunology assets," said Bruce Steel, chief executive officer at Equillium. "Decheng had been looking for a team to advance development of this asset and believe Equillium is an excellent fit based on our immunology expertise and development capabilities. Aligning both parties' interests the program was acquired on favorable terms – there was no upfront payment and milestone payments commence upon FDA approval."

    "Decades of research has identified the AhR pathway as an important physiological regulator of immune homeostasis in barrier tissues," said Francisco J. Quintana, Ph.D., Professor of Neurology at the Ann Romney Center for Neurologic Diseases, at Brigham and Women's Hospital, Harvard Medical School. "Unique to AhR is that its activation can promote both barrier function and anti-inflammatory pathways highlighting it as an attractive therapeutic target. Indeed, the first AhR-activating drug tapinarof (VTAMA®) was recently approved for the treatment of psoriasis and atopic dermatitis while clinical trials are underway to evaluate the effects of AhR modulators in other inflammatory diseases."

    Despite a paradigm shift in our understanding of modulating AhR and the growing level of clinical validation, drug development efforts have been hampered by lack of suitable clinical development candidates. EQ504 is a potent and selective AhR modulator with excellent drug-like properties making it amenable to be formulated for targeted, local delivery such as enteric coating for the treatment of ulcerative colitis or inhaled formulations for the treatment of inflammatory lung diseases.

    "There is significant clinical evidence that AhR modulators are impactful in treating gastrointestinal inflammation where they can resolve inflammation and promote mucosal healing. We believe EQ504 may represent a powerful monotherapy or combination approach to treating ulcerative colitis, where poor mucosal healing limits the majority of patients achieving full clinical remission," said Dr. Stephen Connelly, chief scientific officer at Equillium. "Subject to additional capital, we plan to initiate a phase 1 study to demonstrate targeted proof of mechanism."

    Additional data will be presented next week at the annual meeting of the American Association of Immunologists (AAI) in Honolulu, Hawaii.

    About EQ504

    EQ504 is a potent and selective AhR modulator with a unique, multi-modal, non-immunosuppressive mechanism of action that is complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504 has excellent drug-like properties making it amenable to be formulated for targeted, local delivery such as enteric coating for the treatment of ulcerative colitis or inhaled formulations for the treatment of inflammatory lung diseases.

    About Equillium

    Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company's pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.

    For more information, visit www.equilliumbio.com.

    Forward Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "could", "continue", "expect", "estimate", "may", "plan", "outlook", "future", "potential" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium's plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for initiating and reporting data from a Phase 1 study of EQ504; the ability to raise additional capital to fund development of EQ504; and the potential benefits of EQ504. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium's ability to execute its plans and strategies; Equillium's ability to continue as a going concern; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium's product candidates; changes in the competitive landscape; and Equillium's ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium's strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website and on Equillium's website under the heading "Investors." Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250501399336/en/

    Corporate Contact

    Michael Moore

    Vice President, Investor Relations Officer & Head of Corporate Communications

    619-302-4431

    [email protected]

    Get the next $EQ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $EQ
    SEC Filings

    View All

    SEC Form 8-K filed by Equillium Inc.

    8-K - Equillium, Inc. (0001746466) (Filer)

    10/6/25 4:05:10 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Equillium Inc.

    8-K - Equillium, Inc. (0001746466) (Filer)

    9/19/25 4:06:43 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Equillium Inc.

    424B5 - Equillium, Inc. (0001746466) (Filer)

    9/19/25 4:05:21 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $EQ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Equillium Announces Leadership and Corporate Updates

    LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates. "The updates we announced today mark an important and timely step as we sharpen our therapeutic pipeline focus on advancing EQ504, our novel aryl hydrocarbon receptor (AhR) modulator, into the clinic to treat severe inflammatory diseases," said Bruce Steel, Chief Executive Officer at Equillium. "These changes are intended to strength

    10/6/25 4:02:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Equillium, Inc. (NASDAQ:EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 150,000 shares of common stock to two new employees under Equillium's 2024 Inducement Plan. The Compensation Committee approved the stock option as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $1.74, Equillium's closing stock price on August 29,

    9/3/25 4:05:00 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Connelly Stephen

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:04:34 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Principal Accounting Officer Tom Penny

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:02:46 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Sr. Vice President and COO Zedelmayer Christine

    4 - Equillium, Inc. (0001746466) (Issuer)

    9/3/25 5:00:37 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Equillium from Outperform to Market Perform and set a new price target of $1.00 from $3.00 previously

    3/28/25 8:14:37 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink reiterated coverage on Equillium with a new price target

    SVB Leerink reiterated coverage of Equillium with a rating of Outperform and set a new price target of $14.00 from $18.00 previously

    1/5/22 6:36:04 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Equillium with a new price target

    Stifel resumed coverage of Equillium with a rating of Buy and set a new price target of $12.00

    10/29/21 8:33:13 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Leadership Updates

    Live Leadership Updates

    View All

    NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

    SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M. Bradbury as Strategic and Metabolic Programs Advisor. "We are thrilled to welcome Dan to NeuraClick," said Dr. Subhi Marwari, Chief Executive Officer. "For an early-stage venture, experienced guidance is essential, and Dan's deep expertise in company building and metabolic therapeutics will be invaluable as we advance our pipeline. He is a phenomenal coach on this journey, helping us navigat

    9/23/25 5:30:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium to be included in the Russell Microcap® Index

    Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effective at the open of equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them by total market capitalization. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and va

    6/12/24 8:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

    -Mr. Bradbury has over 35 years of experience leading fast-growing life sciences companies- Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors. "We are delighted to welcome Dan to our Board. His appointment reflects the recent progress we have made with our MyBabyBiome™ study of infant gut health, and our near-term plans to commercialize our first product based on the findings. Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in

    10/23/23 8:00:00 AM ET
    $CSTL
    $EQ
    $ICPT
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $EQ
    Financials

    Live finance-specific insights

    View All

    Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

    Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

    3/27/25 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium Maintains Rights to Itolizumab Following Ono Partnership

    Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

    10/31/24 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab

    Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

    12/6/22 7:00:00 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Equillium Inc.

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    11/14/24 9:50:36 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Equillium Inc.

    SC 13G - Equillium, Inc. (0001746466) (Subject)

    1/19/24 6:03:46 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Equillium Inc. (Amendment)

    SC 13G/A - Equillium, Inc. (0001746466) (Subject)

    3/3/23 9:27:36 AM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care